Synchron Begins Enrollment in Pivotal Trial for Stentrode BCI System
Summary
Synchron announced that it has begun enrolling patients in its pivotal clinical trial evaluating the Stentrode brain-computer interface system. The Stentrode is an endovascular BCI that is delivered through the jugular vein without open-brain surgery, making it less invasive than traditional cortical implants. The trial aims to evaluate the safety and efficacy of the Stentrode for enabling patients with severe paralysis to control digital devices.
Why it matters
This pivotal trial represents a major step toward potential FDA approval and commercialization of the Stentrode, which could become the first commercially available implantable BCI. The endovascular delivery approach avoids open-brain surgery, potentially making BCI technology accessible to a broader patient population. Successful completion of this pivotal trial could establish a new standard for minimally invasive BCI implantation.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial